1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-methyl-3-[[2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-6-yl]amino]phenyl]urea : no description available [CHeBI]
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| allantoic acid | | ureas | mouse metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allantoin | | imidazolidine-2,4-dione;
ureas | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxaluric acid | | 2-oxo monocarboxylic acid;
ureas | Escherichia coli metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 173074 | | aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbamazepine epoxide | | dibenzoazepine;
epoxide;
ureas | allergen;
drug metabolite;
marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimorpholamine | | morpholines;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxymethyltolbutamide | | benzyl alcohols;
sulfonamide;
ureas | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dicyclohexylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbamylhydrazine | | carbohydrazide;
monocarboxylic acid amide;
one-carbon compound;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dimethylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylene urea | | imidazolidinone;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbarson | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbamol | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dulcin | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydantoic acid | | monocarboxylic acid;
N-acylglycine;
ureas | rat metabolite;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neburon | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,1,3,3-tetramethylurea | | ureas | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monolinuron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| siduron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metobromuron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imidocarb | | ureas | antiprotozoal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlormerodrin | | organomercury compound;
ureas | diagnostic agent;
diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorbromuron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbuterol | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iprodione | | benzenes;
dichlorophenyl dicarboximide fungicide;
imidazole fungicide;
imidazolidine-2,4-dione;
ureas | antifungal agrochemical;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imidazolidinyl urea | | ureas | antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dymron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thidiazuron | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lidamidine | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buprofezin | | thiadiazinane;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zileuton | | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycoluril | | azabicycloalkane;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homocitrulline | | amino acid zwitterion;
L-lysine derivative;
non-proteinogenic L-alpha-amino acid;
ureas | human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| talinolol | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mecloralurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dmp 323 | | diazepanone;
ureas | anti-HIV agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amperozide | | diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prochloraz | | amide fungicide;
aromatic ether;
conazole fungicide;
imidazole fungicide;
imidazoles;
trichlorobenzene;
ureas | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biocytin | | azabicycloalkane;
L-alpha-amino acid zwitterion;
L-lysine derivative;
monocarboxylic acid amide;
non-proteinogenic L-alpha-amino acid;
thiabicycloalkane;
ureas | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 10-hydroxycarbamazepine | | carboxamide;
dibenzoazepine;
ureas | anticonvulsant;
drug allergen;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carglumic acid | | N-acyl-L-glutamic acid;
ureas | carbamylphosphate synthetase I activator;
orphan drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ici 89406 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ns 1608 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-bis(3-chlorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allophanic acid | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| birb 796 | | aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eslicarbazepine acetate | | acetate ester;
carboxamide;
dibenzoazepine;
ureas | anticonvulsant;
drug allergen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-mercaptodethiobiotin | | imidazolidinone;
monocarboxylic acid;
thiol;
ureas | Escherichia coli metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,1,3,3-tetraphenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclooctylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-chlorophenyl)-3-(2-ethoxyphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[[4-(methylthio)anilino]-oxomethyl]amino]benzamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pnu 120596 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[[(3,4-dimethylanilino)-oxomethyl]amino]phenyl]-N-methylacetamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methyl-1,3-benzothiazol-2-yl)-3-[3-(methylthio)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,6-dichlorophenyl)-3-(6-methyl-3-pyridinyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xv 638 | | 1,3-thiazoles;
benzamides;
diazepanone;
diol;
secondary alcohol;
secondary carboxamide;
ureas | HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(5-hex-1-ynyl-2-furanyl)-oxomethyl]amino]-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-cyanophenyl)-3-[1-[(4-methoxyphenyl)methyl]-2-oxo-3-pyridinyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N3-(2,3-dimethylphenyl)-N1-(2-methoxyphenyl)piperidine-1,3-dicarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[5-[[anilino(oxo)methyl]amino]-1,3-dimethyl-2-oxo-4-imidazolidinyl]-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-3-[1,1,1-trifluoro-2-(trifluoromethyl)butan-2-yl]urea | | thiadiazoles;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-[1,1,1-trifluoro-2-(trifluoromethyl)butan-2-yl]urea | | thiadiazoles;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-hydroxyphenyl)-3-[1,1,1-trifluoro-2-(trifluoromethyl)butan-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[anilino(oxo)methyl]amino]-4,5-dimethyl-3-thiophenecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1,3-benzothiazol-2-yl)-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-3-(4-chlorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methoxyphenyl)-3-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,5-dichlorophenyl)-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4,5-dihydrothiazol-2-yl)-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-fluoro-5-nitrophenyl)-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclohexyl-3-(2-ethylphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[anilino(oxo)methyl]amino]-N-(2-furanylmethyl)benzamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methoxyphenyl)-1-methyl-3-(1-methyl-5-benzotriazolyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methoxyphenyl)-3-(2-methyl-1,3-benzoxazol-5-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclohexyl-3-(3-ethylphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,4-dichlorophenyl)-3-(1-methyl-3-pyrazolyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[tert-butyl-[(3,5-dimethylphenyl)-oxomethyl]amino]-3-(4-chlorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dichlorophenyl)-3-(6-methylsulfonyl-1,3-benzothiazol-2-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dichlorophenyl)-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[1-methyl-2-(1-pyrrolidinylmethyl)-5-benzimidazolyl]-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-(difluoromethoxy)-4-methylphenyl]-3-(2,4-difluorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-amino-N-(4-methylphenyl)-5-(methylthio)-1,2,4-triazole-4-carboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-chlorophenyl)-3-[5-[(4-chlorophenyl)methylthio]-1,3,4-thiadiazol-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-3-butyl-1-ethylurea | | pyrimidone;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-bromo-2-fluorophenyl)-3-(3-chlorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,5-dimethoxyphenyl)-3-[2-(trifluoromethyl)-1,3-benzodioxol-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-bromophenyl)-3-[2-(2-methoxyphenoxy)ethyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiourea | | one-carbon compound;
thioureas;
ureas | antioxidant;
chromophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,4-difluorophenyl)-3-[(5-methyl-3-phenyl-4-isoxazolyl)methyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-benzyl-N-(3,5-dichlorophenyl)-1,4-diazepane-1-carboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N1-(4-chlorophenyl)-3-(1H-pyrrol-1-ylmethyl)piperidine-1-carboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-fluorophenyl)-3-[2-methyl-5-(1-piperidinylsulfonyl)-3-furanyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-2-[[(4-methylanilino)-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-(4-chlorophenyl)sulfonylethyl]-1-ethyl-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chloro-4-propan-2-ylsulfonyl-2-thiophenyl)-3-(3-nitrophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(5-tert-butyl-2-methyl-3-pyrazolyl)-3-(3,5-dichlorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,5-dichlorophenyl)-3-[2-(2-furanylmethylthio)ethyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methyl-4,7-bis(methylsulfonyl)-3a,5,6,7a-tetrahydro-1H-imidazo[4,5-b]pyrazin-2-one | | imidazopyrazine;
sulfonamide;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[[4,6-bis(1-piperidinyl)-1,3,5-triazin-2-yl]oxy]ethyl]-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[[4,6-bis(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]ethyl]-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1,3-benzodioxol-5-yl)-3-(5-tert-butyl-2-methoxyphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-(4-morpholinyl)-2,1,3-benzoxadiazol-7-yl]-3-(4-nitrophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,5-dimethylphenyl)-3-(9-prop-2-enyl-9-azabicyclo[3.3.1]nonan-3-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[butan-2-yl-[(3,4-dichloroanilino)-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,6-dimethylphenyl)-3-thiophen-2-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-3-thiophen-2-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3,4-dimethylphenyl)-3-[(4-fluorophenyl)methyl]-1,3-diazinane-1-carboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-fluorophenyl)-6-methyl-1-propyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | | 1,2-thiazoles;
indoles;
ureas | receptor modulator;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gw 7647 | | aryl sulfide;
monocarboxylic acid;
ureas | PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,5-dimethoxyphenyl)-3-[5-(2-methyl-1-piperidinyl)-1,3,4-thiadiazol-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-methoxyphenyl)-3-[5-(2-methyl-1-piperidinyl)-1,3,4-thiadiazol-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dichlorophenyl)-3-[1-(4-morpholinyl)-1-phenylpropan-2-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-carbamylglutamate | | glutamic acid derivative;
ureas | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1,3-benzodioxol-5-yl)-3-(4-fluorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(4-chlorophenyl)methyl]-3-(3-fluorophenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-chlorophenyl)-3-[2-(2-furanylmethyl)cyclohexyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,4-dichlorophenyl)-3-[3-(1-imidazolyl)propyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dichlorophenyl)-3-[diethoxyphosphoryl(phenyl)methyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chloro-4-methoxyphenyl)-3-(2-fluorophenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)-3-pyridin-4-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,4-difluorophenyl)-3-[4-(2-pyridinyl)-2-thiazolyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(Chloroacetyl)-N,2-diphenylhydrazinecarboxamide | | ureas | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dichlorophenyl)-3-(1,3,5-trimethyl-4-pyrazolyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(4-methylphenyl)methyl]-1,3-diazinan-2-one | | pyrimidone;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l796778 | | benzenes;
C-nitro compound;
L-lysine derivative;
L-phenylalanine derivative;
methyl ester;
oligopeptide;
secondary carboxamide;
ureas | somatostatin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 166866 | | biaryl;
dimethoxybenzene;
primary arylamine;
pyridopyrimidine;
ureas | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bw b70c | | aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[(3-methoxyanilino)-oxomethyl]amino]benzoic acid | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-methoxyphenyl)-3-[2-(methylthio)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[(2,4-difluoroanilino)-oxomethyl]amino]benzoic acid | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-methoxy-5-methylphenyl)-3-pyridin-4-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dimethoxyphenyl)-3-(2-fluoro-5-methylphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-butan-2-yl-3-(4-ethoxyphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| avibactam | | azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas | antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonafarnib | | benzocycloheptapyridine;
heteroarylpiperidine;
N-acylpiperidine;
organobromine compound;
organochlorine compound;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly2090314 | | diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pimavanserin | | aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas | 5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bx795 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ns3694 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | | tripeptide;
ureas | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyt997 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 0348292 | | monochlorobenzenes;
monofluorobenzenes;
pyridone;
pyrrolidines;
secondary carboxamide;
ureas | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| omecamtiv mecarbil | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| narlaprevir | | azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas | anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly2603618 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,3-dihydro-1H-inden-5-yl)-3-(2-ethoxyphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,3-dichlorophenyl)-3-pyridin-4-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sns 314 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wye 125132 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyclohexyl-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[[(4-methoxyanilino)-oxomethyl]amino]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-methoxyphenyl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclohexanecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2R,3S)-8-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,4,4-trifluoro-N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]butanamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-methoxyphenyl)-1-methylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3R)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-10-[[(4-methoxyanilino)-oxomethyl]amino]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-9-[[(4-methoxyanilino)-oxomethyl]amino]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-phenylurea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| CAY10626 | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenobam | | ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |